Eli Lilly to Acquire Kelonia Therapeutics for $3.25 Billion to Boost Oncology Portfolio

Eli Lilly's $3.25 billion acquisition of Kelonia Therapeutics marks a strategic move into CAR-T therapies and cancer treatments, responding to recent industry M&A trends. This deal not only revitalizes Kelonia's potential after financial struggles but also signals Lilly's broader push into genetic and oncology medicines. Going forward, Lilly's focus will likely be on integrating Kelonia's innovative therapies to expand its market share and address unmet cancer treatment needs.